KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Total Current Liabilities (2016 - 2025)

Novavax has reported Total Current Liabilities over the past 16 years, most recently at $460.0 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $460.0 million for Q4 2025, down 60.16% from a year ago — trailing twelve months through Dec 2025 was $460.0 million (down 60.16% YoY), and the annual figure for FY2025 was $460.0 million, down 60.16%.
  • Total Current Liabilities for Q4 2025 was $460.0 million at Novavax, up from $429.9 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for NVAX hit a ceiling of $2.5 billion in Q4 2022 and a floor of $389.1 million in Q2 2025.
  • Median Total Current Liabilities over the past 5 years was $1.5 billion (2023), compared with a mean of $1.4 billion.
  • Biggest five-year swings in Total Current Liabilities: surged 6266.85% in 2021 and later crashed 66.39% in 2025.
  • Novavax's Total Current Liabilities stood at $2.4 billion in 2021, then grew by 2.91% to $2.5 billion in 2022, then tumbled by 33.53% to $1.6 billion in 2023, then decreased by 29.4% to $1.2 billion in 2024, then plummeted by 60.16% to $460.0 million in 2025.
  • The last three reported values for Total Current Liabilities were $460.0 million (Q4 2025), $429.9 million (Q3 2025), and $389.1 million (Q2 2025) per Business Quant data.